Aradigm
Hayward
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $75.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2016)
- Ticker: nasdaq:ARDM
- Website: aradigm.com
- Phone: +1 510 265-9000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aradigm-34036 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.